Tracer kinetic modeling in nuclear cardiology

Journal of Nuclear Cardiology

Volumn 7, Issue 6, 2000, Pages 686-700

  DeGrado, Timothy R ^a   Bergmann, Steven R ^b   Ng, Chin K ^a   Raffel, David M ^c  

^a YALE UNIVERSITY   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; 3 HYDROXYEPHEDRINE; ACETIC ACID C 11; ADRENALIN; AMMONIA; CARBON MONOXIDE; FATTY ACID; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GLUCOSE; IODINE 123; LONG CHAIN FATTY ACID; MICROSPHERE; MISONIDAZOLE; NITROGEN 13; NITROIMIDAZOLE DERIVATIVE; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; OXYGEN; PALMITIC ACID C 11; PHENYLEPHRINE; RADIOPHARMACEUTICAL AGENT; RUBIDIUM 82; TEBOROXIME TC 99M; TECHNETIUM 99M; THALLIUM 201; TRACER; UPENAZIME TC 99M; WATER O 15;

AEROBIC METABOLISM; ANIMAL TISSUE; ARTICLE; CARDIOLOGY; COMPARTMENT MODEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FATTY ACID METABOLISM; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HALF LIFE TIME; HALOGENATION; HEART INNERVATION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE PERFUSION; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; ISOTOPE LABELING; METABOLIC RATE; MODEL; NONHUMAN; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC INNERVATION; TECHNIQUE;

EID: 0034525824     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1067/mnc.2000.111127     Document Type: Article

References (108)

1. Measurement of regional tissue and blood radiotracer concentrations from serial tomographic images of the heart
2. 15O
3. 15O and dynamic positron emission tomography. Strategy for quantification in relation to partial-volume effect
4. Nitrogen-13-ammonia myocardial imaging at rest and with exercise in normal volunteers: Quantification of absolute myocardial perfusion with dynamic positron emission tomography
5. 13N-ammonia and reoriented dynamic positron emission tomographic imaging
6. A region of interest strategy for minimizing resolution distortions in quantitative myocardial studies
7. Quantification of myocardial blood flow using dynamic nitrogen-13 ammonia PET studies and factor analysis of dynamic structures
8. N-13 ammonia as an indicator of myocardial blood flow
9. Simultaneous in vitro and in vivo validation of N-13-ammonia for the assessment of regional myocardial blood flow
10. A simplified method for quantification of myocardial blood flow using nitrogen-13-ammonia and dynamic PET
11. 13N-ammonia and PET
12. Quantification of myocardial perfusion with positron emission tomography
13. Noninvasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography
14. 15O and positron emission tomography: Assessment and error analysis of a mathematical approach
15. Noninvasive quantification of regional myocardial blood flow in coronary artery disease with oxygen-15-labeled carbon dioxide inhalation and positron emission tomography
16. Myocardial blood flow: Comparison of oxygen-15-water bolus injection, slow infusion and oxygen-15-carbon dioxide slow inhalation
17. Concordance of nutritive myocardial perfusion reserve and flow velocity reserve in conductance vessels in patients with chest pain with angiographically normal coronary arteries
18. Assessment of blood flow distal to coronary artery stenoses: Correlations between myocardial positron emission tomography and post-stenotic intracoronary Doppler flow reserve
19. Noninvasive delineation of the effects of moderate aging on myocardial perfusion
20. Relation between myocardial blood flow and the severity of coronary artery stenosis
21. Clot-selective coronary thrombolysis with tissue-type plasminogen activator
22. The time course of restoration of nutritive perfusion, myocardial oxygen consumption, and regional function after coronary thrombolysis
23. 15O
24. Persistence of coronary vasodilator responsivity after cardiac transplantation
25. Myocardial tissue fraction-correction for partial volume effects and measure of tissue viability
26. Preoperative prediction of outcome of coronary revascularization using positron emission tomography
27. 15O-water and dynamic positron emission tomography
28. Heterogeneity of myocardial perfusion provides the physiological basis of "perfusable tissue index
29. A retrospective study of the diagnostic accuracy of a community hospital-based PET center for the detection of coronary artery disease using rubidium-82
30. Myocardial perfusion with rubidium-82. II. Effects of metabolic and pharmacologic interventions
31. Noninvasive quantitation of regional myocardial blood flow with rubidium-82 and positron emission tomography: Exploration of a mathematical model
32. Implementation and evaluation of a two-compartment model for quantification of myocardial perfusion with rubidium-82 and positron emission tomography
33. Myocardial perfusion with rubidium-82. I. Measurement of extraction fraction and flow with external detectors
34. Improving PET-based physiological quantification through wavelet denoising
35. Quantification of myocardial perfusion in human subjects using rubidium-82 and wavelet-based noise reduction
36. Kinetics of rubidium-82 after coronary occlusion and reperfusion: Assessment of patency and viability in open-chested dogs
37. Myocardial metabolism of fluorodeoxyglucose compared to cell membrane integrity for the potassium analogue rubidium-82 for assessing infarct size in man by PET
38. Experimental verification of technetium 99-m-labeled teboroxime kinetic parameters in the myocardium with dynamic single-photon emission computed extravascular contamination
39. A simulation of dynamic SPECT using radiopharmaceuticals with rapid clearance
40. Myocardial clearance kinetics of technetium-99m-SQ30217: A marker of regional myocardial blood flow
41. Compartmental analysis of technetium-99m-teboroxime kinetics employing fast dynamic SPECT at rest and stress
42. Quantitative assessment of regional myocardial blood flow with thallium-201 and SPECT
43. Kinetics of transport and phosphorylation of 2-fluoro-2-deoxy-D-glucose in rat brain
44. The use of deoxyfluoro-D-glucopyranoses and related compound in a study of yeast hexokinase specificity
45. The activity of fructose 1, 6 diphosphatase, fructokinase, and phosphoenolpyruvate carboxykinase in white and red muscle
46. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: Validation of method
47. Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose
48. Evaluation of compartmental and spectral analysis models of [18F]FDG kinetics for heart and brain studies with PET
49. Sensitivity of myocardial fluorodeoxyglucose lumped constant to glucose and insulin
50. Fundamental limitations of [18F]2-deoxy-2-fluoro-D-glucose for assessing myocardial glucose uptake
51. Fluorodeoxyglucose rate constants, lumped constant, and glucose metabolic rate in rabbit heart
52. Profound underestimation of glucose uptake by [18F]2-deoxy-2-fluoroglucose in reperfused rat heart muscle
53. Glucose metabolism in reperfused myocardium measured by (2-18F)2-fluorodeoxyglucose and PET
54. Glucose uptake and lumped constant variability in normal human hearts determined with [18F]fluorodeoxyglucose
55. Effect of hyperinsulinemia on myocardial F-18 labeled fluorodeoxyglucose uptake in humans
56. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans
57. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography
58. Delineation of myocardial oxygen utilization with carbon-11-labeled acetate
59. Radiolabeled acetate as a tracer of myocardial tricarboxylic acid cycle flux
60. 11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium
61. Noninvasive estimation of regional myocardial oxygen consumption by positron emission tomography with carbon-11 acetate in patients with myocardial infarction
62. Validation of a model for [1-11C]acetate as a tracer of cardiac oxidative metabolism
63. Compartment model for measuring myocardial oxygen consumption using [1-11C]acetate
64. Simultaneous measurement of myocardial oxygen consumption and blood flow using (1-carbon-11)acetate
65. Myocardial uptake of carbon-11-acetate as an indirect estimate of regional myocardial blood flow
66. Noninvasive estimation of myocardial efficiency using positron emission tomography and carbon-11 acetate-comparison between the normal and failing human heart
67. Effect of carbon-11-acetate recirculation on estimates of myocardial oxygen consumption by PET
68. Delineation of myocardial fatty acid metabolism with positron emission tomography
69. 11C]palmitate in rabbit hearts
70. 11C-palmitate
71. C-11 labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron-computed tomography. I. Kinetics of C-11 palmitic acid in normal myocardium
72. PET studies of the heart
73. Detection and assessment by positron emission tomography of a genetically determined defect in myocardial fatty acid utilization (long-chain acyl-CoA dehydrogenase deficiency)
74. Quantitation of myocardial fatty acid metabolism using PET
75. Fatty acids for myocardial imaging
76. Variables of myocardial backdiffusion, determined with 17-iodo-131-heptadecanoic acid in the normal dog heart
77. 123I-16-iodo-9-hexadecenoic acid in an isolated rat heart. Validation by comparison with experimental measurements
78. Quantitative analysis of myocardial kinetics of 15-p-[iodine-125]iodophenylpentadecanoic acid
79. BMIPP-design and development
80. Radioiodinated p-phenylene bridged fatty acids as new myocardial imaging agents: Synthesis and biodistribution in rats
81. Kinetics of 14(R, S)-fluorine-18-fluoro-6-thia-heptadecanoic acid in normal human hearts at rest, during exercise and after dipyridamole injection
82. 18F]Fluoro-6-thia-heptadecanoic acid (FTHA): Evaluation in mouse of a new in vivo probe of myocardial utilization of long chain fatty acids
83. Comparison of fatty acid tracers FTHA and BMIPP retention during myocardial ischemia and hypoxia
84. 18F-labeled 4-thia palmitate (FTP) as a pet tracer of myocardial fatty acid oxidation
85. Fluoromisonidazole: A metabolic marker of myocyte hypoxia
86. Myocardial kinetics of fluorine-18-misonidazole: A marker of hypoxic myocardium
87. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography
88. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: A potential approach for identification of jeopardized myocardium
89. Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia
90. Kinetic analysis of Tc-99m labeled nitroimidazole (BMS-181321) as a tracer of myocardial hypoxia
91. Technetium-99 nitroimidazole (BMS181321): A positive imaging agent for detecting myocardial ischemia
92. Kinetics of a putative hypoxic tracer, 99mTc-HL91, in normoxic, hypoxic, ischemic, and stunned myocardium
93. Myocardial imaging with a radioiodinated norepinephrine storage analog
94. Cardiac studies with metaiodobenzylguanidine: A critique of methods and interpretation of results
95. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure
96. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy
97. Iodine-123 meta-iodobenzylguanidine scintigraphy: A noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy
98. 201TI in congestive heart failure
99. Synthesis and preliminary evaluation of carbon-11-meta-hydroxyephedrine: A false transmitter agent for heart neuronal imaging
100. 11C]epinephrine for routine PET studies in humans
101. 11C](-)-a-a-dideuterophenylephrine for in vivo kinetic isotope studies
102. 76Br-metabromobenzylguanidine: A PET radiotracer for mapping of sympathetic nerves of the heart
103. 18F]fluorobenzylguanidine in the isolated rat heart
104. 18F]fluorobenzylguanidine kinetics in a canine coronary artery occlusion model
105. 18F]fluorodopamine for PET studies of sympathetic nervous tissue
106. Carbon-11 hydroxyephedrine with positron emission tomography for serial assessment of cardiac adrenergic neuronal function after acute myocardial infarction in humans
107. Clinical evaluation of carbon-11-phenylephrine: MAO sensitive marker of cardiac sympathetic neurons
108. Quantitation of presynaptic cardiac sympathetic function with carbon-11-meta-hydroxyephedrine